African ancestry and innate immunity contribute to the incidence of multicentric Castleman’s disease in HIV-1/Kaposi’s sarcoma herpesvirus-coinfected individuals

Author： Westrop Samantha J   Lagos Dimitrios   Boshoff Chris   Bower Mark   Imami Nesrina  

Publisher： Future Medicine

ISSN： 1746-0794

Source： Future Virology, Vol.7, Iss.7, 2012-07, pp. : 729-734

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Kaposi’s sarcoma-associated herpesvirus and innate immunity

By West John A   Damania Blossom  

Future Virology, Vol. 5, Iss. 2, 2010-03 ,pp. : 185-196

Future Medicine

Access to resources Recommend Favorite

Why is Kaposi’s sarcoma-associated herpesvirus not ubiquitous in the human population?

By Bagni Rachel   Whitby Denise  

Future Virology, Vol. 2, Iss. 3, 2007-05 ,pp. : 243-246

Future Medicine

Access to resources Recommend Favorite

Novel pharmacological therapies for the treatment of AIDS-related Kaposi’s sarcoma

By Cattelan Anna Maria   Trevenzoli Marco   Aversa Savina Maria Lucia  

Expert Opinion on Investigational Drugs, Vol. 13, Iss. 5, 2004-05 ,pp. : 501-513

Informa Healthcare

Access to resources Recommend Favorite

Clinical Use of Rituximab in Patients with HIV Related Lymphoma and Multicentric Castleman's Disease

By  

Current Drug Delivery, Vol. 9, Iss. 1, 2012-01 ,pp. : 41-51

Bentham Science Publishers

Access to resources Recommend Favorite

Viral Latent Proteins as Targets for Kaposi's Sarcoma and Kaposi's Sarcoma-associated Herpesvirus (KSHV / HHV-8) Induced Lymphoma

By  

Current Drug Targets - Infectious Disorders, Vol. 3, Iss. 2, 2003-06 ,pp. : 129-135

Bentham Science Publishers

Access to resources Recommend Favorite